MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer - Wikidata - awgldk - TriplyDB

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

http://www.wikidata.org/entity/Q29617772

about

PD-L1 expression in human cancers and its association with clinical outcomes Immunobiology and immunotherapy in genitourinary malignancies The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Immune checkpoint blockade therapy for bladder cancer treatment Novel immunotherapeutic approaches to the treatment of urothelial carcinoma Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University Emerging molecular classifications and therapeutic implications for gastric cancer Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Lymphocyte-activation gene-3, an important immune checkpoint in cancer Systemic Immunotherapy for the Treatment of Brain Metastases Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?Clinical utility of nivolumab in the treatment of advanced melanoma Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer Novel technologies and emerging biomarkers for personalized cancer immunotherapy Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives Predictors of clinical response to immunotherapy with or without radiotherapy Expanding the antimalarial toolkit: Targeting host-parasite interactions Current status of immunotherapy Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Muscle-invasive urothelial bladder cancer: an update on systemic therapy Intravesical immunotherapy in nonmuscle invasive bladder cancer Engineering opportunities in cancer immunotherapy CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Antagonists of PD-1 and PD-L1 in Cancer Treatment Strategies for combining immunotherapy with radiation for anticancer therapy

P2860

Q26738361-FB361D8F-603C-470C-87B2-E145B5FC05A1 Q26738668-9E495350-98C7-47FF-AD35-4F3C787F652C Q26738677-DBBC9974-5506-4C8C-B9FD-516310F71572 Q26738729-342B74FD-F56C-42CD-A58D-118C4EA24C20 Q26740065-8330EEE3-5E9E-4397-8A91-F05C3943A459 Q26741101-B77281B1-182C-4302-90FE-31012B9E909B Q26742107-3C25D6ED-9AE3-4EE7-9DD7-160BC6370BFD Q26744139-FA59BF8A-D5F2-410E-AB6A-99EBABEBA24A Q26744347-8D2D114D-DDEB-490D-9548-B07CB7D9628E Q26744758-A259FA87-0FA0-41E4-8C3F-AA7FAA6D2A6A Q26744799-CDA13B58-8275-49F5-8F73-10A2AD8C2662 Q26745525-BE99BBDA-BED8-43D5-A5D5-DD265B2406B9 Q26745590-6F96C641-BE02-44B5-A60C-28C97CDC0B28 Q26746209-35D77CE7-94E6-402F-9D3D-D716560A11FC Q26750891-2F5398AE-AE9D-4041-9DA8-556C93CAB21D Q26751230-5D2580D5-52E0-4BCB-96E8-831877B34D22 Q26751268-EAC4A699-6683-4116-A0F9-85CBAD4D08AA Q26765115-2786E3AA-CBD4-4DBA-B941-04B9CFE17BEA Q26766285-A1E27567-60B1-4119-902C-DFFF1BC4B7F9 Q26768641-BEFE827F-1377-4ECA-A7E4-F83A3638E0D8 Q26769728-46EE37AC-9548-434C-BA72-B3AC7B03D202 Q26769884-3A1D6FA2-0117-4B8A-A129-A76EB266B43A Q26770422-C2265877-EB60-406C-A6C8-BA2E4782667F Q26770780-32CD4655-450C-441D-B76C-B66F05D70429 Q26771263-50C7F5A0-E7EB-47F6-BA16-DDB0C830ABEC Q26771870-C0DE2EF3-EAD8-4C26-B2EE-CD913890370F Q26772866-46DC63DE-708D-4014-93B3-5B12AD50AA14 Q26773314-BBA812A1-E24E-48CB-9378-9578403D0610 Q26773664-498171F4-40D6-4B83-BE65-C4363F3ADF5E Q26774690-97D63378-E13E-45E5-B54A-CC0562BAA585 Q26775034-CB45360C-06E4-4B2A-B69A-9F426B20BC95 Q26775780-9D859FAD-4F8C-4445-BBE1-36E21C721519 Q26775979-BD3B7A3A-2A05-4014-AEA3-B5C08B0E4D8A Q26776373-E011A5E1-FED4-4FF0-B7A8-DB870019BCEB Q26777563-C32B2714-DC6D-4697-A52A-F33553D924C0 Q26778296-F0B77DC9-760A-4A3B-8CFD-1657C85B311F Q26778793-16EFD16C-5528-4EEE-9F39-0100EFA20714 Q26779184-726F8925-2F55-49CF-99A9-25A82A508FF7 Q26796311-138489B5-DD19-4B36-8A71-B0532A93F6E0 Q26796675-DBA9E098-0C97-42F5-9694-807A52C21EC8

P2860

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

http://www.wikidata.org/entity/Q29617772

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@ast

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@en

type

label

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@ast

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@en

prefLabel

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@ast

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@en

P1433

Q29617772-71F21F68-2280-49C5-88EC-24E0CE243F9E

P1476

Q29617772-7813815F-6856-4CEA-A04C-8B13A78F363F

P2093

Q29617772-20791E50-CF43-4AA8-8E7B-BB010EA0E725

Q29617772-291EE738-B37C-47EA-A701-3A69CF8463EA

Q29617772-34D27D69-5435-46AC-BE48-7293E1236A34

Q29617772-3CD4A3E0-C2C1-4CAC-AF4F-30FC25718EAF

Q29617772-72D99C69-CD60-4AB2-A9C5-50DCF4CD7025

Q29617772-99FFE8A3-8E9E-47FC-88BE-4F6615CD03EA

Q29617772-B3E8097D-3DAD-49BD-8B9F-C5592B8DB909

Q29617772-BA414DB4-71A6-4499-AD01-EDB1A24F74C1

Q29617772-BE42E6E5-5F31-404B-86F7-98E4F96895C6

Q29617772-D9842A61-10EE-491A-AE35-5D25A0B9427D

P2888

Q29617772-97EF344C-531A-4CEE-9B58-BB862BB2E72A

P304

Q29617772-2AA9A428-1CCF-48E5-9C1B-0862615ADCE8

P31

Q29617772-E628D4FC-FB02-44D0-9845-B06238E8BA9C

P3181

Q29617772-A137E7F8-172E-4231-82F3-420AAA2107F4

P356

Q29617772-72E049F8-4FB0-4FF5-95B8-C82DCEC1316E

P407

Q29617772-8790CCF1-852A-40F2-96CB-4A383190838F

P433

Q29617772-F48C65DE-EDE7-4A88-A1F3-808A4FAF0876

P478

Q29617772-D0611D9F-62B2-49D7-9FE0-656BC91B63D1

P50

Q29617772-2ED6E6E9-E3D6-4D52-AF5A-4F4BA1B53E03

Q29617772-E2428AA8-44DB-443C-B5FF-533D59949282

P577

Q29617772-5056E8FA-1EC8-406A-9CBF-D70E77DE1467

P5875

Q29617772-FE6292CD-E8B2-4213-BEEB-105DBF43C06C

P6179

Q29617772-5F211CED-CB1C-487E-81DB-A48B8A5B3CB6

P698

Q29617772-F1C3C397-39B0-4D49-A3D1-43DEECCD4101

P3181

P356

P1433

P1476

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

@en

P2093

Cristina Cruz

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

Fadi S Braiteh

http://www.w3.org/2001/XMLSchema#string

Gregg D Fine

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Joseph Paul Eder

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Priti S Hegde

http://www.w3.org/2001/XMLSchema#string

Siew-leng Teng

http://www.w3.org/2001/XMLSchema#string

Thomas Powles

http://www.w3.org/2001/XMLSchema#string

P2888

P304

558-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

380098

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE13904

http://www.w3.org/2001/XMLSchema#string

P407

P433

7528

http://www.w3.org/2001/XMLSchema#string

P478

515

http://www.w3.org/2001/XMLSchema#string

P50

Joaquim Bellmunt

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268874197

http://www.w3.org/2001/XMLSchema#string

P6179

1003953337

http://www.w3.org/2001/XMLSchema#string

P698

25428503

http://www.w3.org/2001/XMLSchema#string